Cannabinoids—via CB1 and/or CB2 receptor activation—exert pharmacological actions which are potentially beneficial in IBS (Izzo and Coutts, 2005; Storr et al., 2008). The gene discussed is CNR1; the disease is irritable bowel syndrome.